참고문헌 (68)

1. Nat. Genet. Andersen 3 118 1993 10.1038/ng0293-118 Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines 

   상세보기

2. J. Transl. Med. Ascierto 12 116 2014 10.1186/1479-5876-12-116 Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort 

   상세보기

3. J. Clin. Oncol. Azimi 30 2678 2012 10.1200/JCO.2011.37.8539 Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma 

   상세보기

4. Int. J. Cancer Baade 130 170 2012 10.1002/ijc.25996 Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990-2006 

   상세보기

5. J. Clin. Oncol. Balch 27 6199 2009 10.1200/JCO.2009.23.4799 Final version of 2009 AJCC melanoma staging and classification 

   상세보기

6. J. Clin. Oncol. Balch 28 2452 2010 10.1200/JCO.2009.27.1627 Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases 

   상세보기

7. Nature Berger 485 502 2012 10.1038/nature11071 Melanoma genome sequencing reveals frequent PREX2 mutations 

   상세보기

8. Proc. Natl. Acad. Sci. USA Bogunovic 106 20429 2009 10.1073/pnas.0905139106 Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival 

   상세보기

9. N. Engl. J. Med. Brahmer 366 2455 2012 10.1056/NEJMoa1200694 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer 

   상세보기

10. Photochem. Photobiol. Brash 91 15 2015 10.1111/php.12377 UV signature mutations 

    상세보기

11. Cell Brennan 155 462 2013 10.1016/j.cell.2013.09.034 The somatic genomic landscape of glioblastoma 

    상세보기

12. Nat. Biotechnol. Carter 30 413 2012 10.1038/nbt.2203 Absolute quantification of somatic DNA alterations in human cancer 

    상세보기

13. JAMA Carvajal 305 2327 2011 10.1001/jama.2011.746 KIT as a therapeutic target in metastatic melanoma 

    상세보기

14. J. Invest. Dermatol. Criscione 130 793 2010 10.1038/jid.2009.328 Melanoma thickness trends in the United States, 1988-2006 

    상세보기

15. N. Engl. J. Med. Curtin 353 2135 2005 10.1056/NEJMoa050092 Distinct sets of genetic alterations in melanoma 

    상세보기

16. Surg. Gynecol. Obstet. Dasgupta 117 341 1963 Malignant Melanoma of Unknown Primary Origin 

    상세보기

17. Br. J. Cancer Draper 53 661 1986 10.1038/bjc.1986.110 Second primary neoplasms in patients with retinoblastoma 

    상세보기

18. Oncotarget Dutton-Regester 5 2912 2014 10.18632/oncotarget.2048 A highly recurrent RPS27 5′UTR mutation in melanoma 

    상세보기

19. Lancet Eggermont 372 117 2008 10.1016/S0140-6736(08)61033-8 Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial 

    상세보기

20. Cancer Res. Erdag 72 1070 2012 10.1158/0008-5472.CAN-11-3218 Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma 

    상세보기

21. Curr. Opin. Ophthalmol. Field 25 234 2014 10.1097/ICU.0000000000000051 Recent developments in prognostic and predictive testing in uveal melanoma 

    상세보기

22. PLoS ONE Frederick 9 e101286 2014 10.1371/journal.pone.0101286 Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics 

    상세보기

23. N. Engl. J. Med. Gershenwald 364 1738 2011 10.1056/NEJMct1002967 Sentinel-lymph-node biopsy for cutaneous melanoma 

    상세보기

24. Mol. Cancer Res. Gold 12 433 2014 10.1158/1541-7786.MCR-13-0422 PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition 

    상세보기

25. N. Engl. J. Med. Hamid 369 134 2013 10.1056/NEJMoa1305133 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma 

    상세보기

26. Nat. Med. Helming 20 251 2014 10.1038/nm.3480 ARID1B is a specific vulnerability in ARID1A-mutant cancers 

    상세보기

27. J. Clin. Oncol. Hodi 26 2046 2008 10.1200/JCO.2007.14.0707 Major response to imatinib mesylate in KIT-mutated melanoma 

    상세보기

28. Cell Hodis 150 251 2012 10.1016/j.cell.2012.06.024 A landscape of driver mutations in melanoma 

    상세보기

29. Science Horn 339 959 2013 10.1126/science.1230062 TERT promoter mutations in familial and sporadic melanoma 

    상세보기

30. Science Huang 339 957 2013 10.1126/science.1229259 Highly recurrent TERT promoter mutations in human melanoma 

    상세보기

31. J. Invest. Dermatol. Jayaraman 134 213 2014 10.1038/jid.2013.276 Mutational landscape of basal cell carcinomas by whole-exome sequencing 

    상세보기

32. Clin. Cancer Res. Ji 19 4383 2013 10.1158/1078-0432.CCR-13-0074 Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth 

    상세보기

33. J. Clin. Oncol. Kirkwood 14 7 1996 10.1200/JCO.1996.14.1.7 Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 

    상세보기

34. Nat. Genet. Krauthammer 44 1006 2012 10.1038/ng.2359 Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma 

    상세보기

35. Acta Neuropathol. Kusters-Vandevelde 119 317 2010 10.1007/s00401-009-0611-3 Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system 

    상세보기

36. Nature Lawrence 499 214 2013 10.1038/nature12213 Mutational heterogeneity in cancer and the search for new cancer-associated genes 

    상세보기

37. Nature Lawrence 505 495 2014 10.1038/nature12912 Discovery and saturation analysis of cancer genes across 21 tumour types 

    상세보기

38. Biochem. Biophys. Res. Commun. Lopez 398 585 2010 10.1016/j.bbrc.2010.06.125 IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain 

    상세보기

39. Pigment Cell Melanoma Res. Lutzky 21 492 2008 10.1111/j.1755-148X.2008.00475.x Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation 

    상세보기

40. Cancer Discov. Maertens 3 338 2013 10.1158/2159-8290.CD-12-0313 Elucidating distinct roles for NF1 in melanomagenesis 

    상세보기

41. J. Invest. Dermatol. Mann 133 509 2013 10.1038/jid.2012.283 BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma 

    상세보기

42. J. Clin. Oncol. McArthur 31 499 2013 10.1200/JCO.2012.45.5568 Targeting oncogenic drivers and the immune system in melanoma 

    상세보기

43. Lab. Invest. Mihm 74 43 1996 Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response 

    상세보기

44. N. Engl. J. Med. Morton 370 599 2014 10.1056/NEJMoa1310460 Final trial report of sentinel-node biopsy versus nodal observation in melanoma 

    상세보기

45. Nat. Genet. Nikolaev 44 133 2012 10.1038/ng.1026 Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma 

    상세보기

46. Cancer Res. Nissan 74 2340 2014 10.1158/0008-5472.CAN-13-2625 Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence 

    상세보기

47. Cancer Cell Noushmehr 17 510 2010 10.1016/j.ccr.2010.03.017 Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma 

    상세보기

48. Nat. Genet. Pollock 33 19 2003 10.1038/ng1054 High frequency of BRAF mutations in nevi 

    상세보기

49. PLoS ONE Rakosy 8 e54958 2013 10.1371/journal.pone.0054958 Integrative genomics identifies gene signature associated with melanoma ulceration 

    상세보기

50. Pigment Cell Melanoma Res. Ranzani 28 117 2015 10.1111/pcmr.12316 BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib 

    상세보기

51. Nat. Med. Robbins 19 747 2013 10.1038/nm.3161 Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells 

    상세보기

52. Lancet Robert 384 1109 2014 10.1016/S0140-6736(14)60958-2 Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial 

    상세보기

53. J. Cutan. Pathol. Santa Cruz 24 533 1997 10.1111/j.1600-0560.1997.tb01457.x Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin 

    상세보기

54. Cancer Res. Shields 67 1502 2007 10.1158/0008-5472.CAN-06-3311 Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma 

    상세보기

55. N. Engl. J. Med. Snyder 371 2189 2014 10.1056/NEJMoa1406498 Genetic basis for clinical response to CTLA-4 blockade in melanoma 

    상세보기

56. J. Med. Chem. Sun 57 1454 2014 10.1021/jm401753e Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development 

    상세보기

57. Nature 455 1061 2008 10.1038/nature07385 Comprehensive genomic characterization defines human glioblastoma genes and core pathways 

    상세보기

58. Nature 489 519 2012 10.1038/nature11404 Comprehensive genomic characterization of squamous cell lung cancers 

    상세보기

59. Nature 507 315 2014 10.1038/nature12965 Comprehensive molecular characterization of urothelial bladder carcinoma 

    상세보기

60. Nature 511 543 2014 10.1038/nature13385 Comprehensive molecular profiling of lung adenocarcinoma 

    상세보기

61. J. Invest. Dermatol. Terheyden 130 314 2010 10.1038/jid.2009.197 Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene 

    상세보기

62. N. Engl. J. Med. Topalian 366 2443 2012 10.1056/NEJMoa1200690 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer 

    상세보기

63. Genes Dev. Tsao 26 1131 2012 10.1101/gad.191999.112 Melanoma: from mutations to medicine 

    상세보기

64. Nature Tumeh 515 568 2014 10.1038/nature13954 PD-1 blockade induces responses by inhibiting adaptive immune resistance 

    상세보기

65. Cancer Discov. Van Allen 4 94 2014 10.1158/2159-8290.CD-13-0617 The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma 

    상세보기

66. Cancer Res. Watson 74 4845 2014 10.1158/0008-5472.CAN-14-1232-T The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF 

    상세보기

67. Cancer Discov. Whittaker 3 350 2013 10.1158/2159-8290.CD-12-0470 A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition 

    상세보기

68. J. Natl. Cancer Inst. Winnepenninckx 98 472 2006 10.1093/jnci/djj103 Gene expression profiling of primary cutaneous melanoma and clinical outcome 

    상세보기